Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Re-Do Celebrex GI Outcome Study After Pharmacia Merger

Executive Summary

Pfizer's post-merger plans for Celebrex include a second gastrointestinal outcomes study to demonstrate a safety benefit for the COX-2 inhibitor
Advertisement

Related Content

Merck Vioxx Formulary Status Retained Since VIGOR GI, CV Label Change
Merck Vioxx Formulary Status Retained Since VIGOR GI, CV Label Change
Bear Stearns Healthcare Conference In Brief
Bear Stearns Healthcare Conference In Brief
Chronic Pain Standard Proposed By FDA Too Strict, Four Trials OK, Cmte Says
Pfizer’s Friendly Tack: McKinnell Shares Credit With Hassan, Offers No. 2 Spot
Celebrex Label Update Has CV Profile Similar To NSAIDs, No New GI Safety
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?
Pfizer/Pharmacia Bextra Will Be Premium Priced, In Pharmacies Feb. 15
Advertisement
UsernamePublicRestriction

Register

PS040235

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel